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Aims Current guidelines recommend stopping oral anticoagulation (OAC) and starting heparin infusion before implanting/
replacing a pacemaker/implantable cardioverter-deﬁbrillator (ICD) in patients with high risk for thrombo-embolic
events. The aim of this study was to demonstrate that the maintenance of OAC during device implantation/replace-
ment is as safe as bridging to intravenous heparin and shortens in-hospital stay.
Methods
and results
A cohort of 101 consecutive patients with high risk for embolic events and indication for implant/replacement of a
pacemaker/ICD were randomized to two anticoagulant strategies: bridging from OAC to heparin infusion (n ¼ 51) vs.
maintenance of OAC to reach an INR ¼ 2+0.3 at the day of the procedure (n ¼ 50). Haemorrhagic and thrombo-
embolic complications were evaluated at discharge, 15 and 45 days after the procedure. A total of 4/51 patients
(7.8%) from heparin group and 4/50 (8.0%) from the OAC group developed pocket haematoma following the
implant (P ¼ 1.00). One haematoma in each group required evacuation (1.9 vs. 2%, P ¼ 1.00). No other haemorrha-
gic events or embolic complications developed during the follow-up. Duration of the hospital stay was longer in the
heparin group [median of 5 (4–7) vs. 2 (1–4) days; P , 0.001].
Conclusion Implant of devices maintaining OAC is as safe as bridging to heparin infusion and allows a signiﬁcant reduction of
in-hospital stay.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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Introduction
Oral anticoagulation (OAC) is commonly used for the prevention
of thrombo-embolic events. Peri-operative management of
patients with high risk of thrombo-embolic events is a relevant
and common clinical problem. In these patients, interrupting antic-
oagulation might promote embolic events such as cerebral stroke
or prosthetic thrombosis. Conversely, peri-operative maintenance
of OAC may increase the risk of post-operative bleeding. Kearon
and Hirsh
1 suggested the discontinuation of OAC and the initiation
of intravenous (i.v.) heparin or low-molecular-weight heparin as a
‘bridging’ therapy. Other studies have shown little or no increased
risk of bleeding with the maintenance of OAC in low-risk pro-
cedures such as dental work, arthrocentesis, cataract surgery,
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2 Larson et al.
3 reported that a
moderate-intensity anticoagulant therapy with OAC targeting a
goal INR 1.5–2.0 appears to be a safe and feasible method for pre-
venting thrombo-embolic complications in these patients.
The use of i.v. heparin that current guidelines recommend in
these patients
4 has been associated with an increased risk of hae-
matoma,
5,6 and the maintenance of OAC did not increase the rate
of pocket haematoma in two previous small series.
7,8 The aim of
this study was to demonstrate that the maintenance of OAC
during device implantation or replacement is as safe as bridging
to i.v. heparin in patients with high risk of thrombo-embolic
events. The primary comparison was the incidence of pocket hae-
matomas and/or thrombo-embolic events during a 45-day period
following the procedure. The secondary endpoint was to
compare the duration of the hospital stay between both groups.
Methods
This is a prospective and randomized single-centre study approved by
the Institutional Human Research Committee.
Inclusion criteria
Patients on chronic OAC who required implantation/replacement of a
pacemaker or an implantable cardiac deﬁbrillator (ICD) were included
in the study if they fulﬁlled any of the following conditions that imply a
high risk for embolic events:
9 (i) mechanical prosthetic valve; (ii) atrial
ﬁbrillation (AF) with previous stroke, transient ischaemic attack (TIA),
systemic embolic event, mitral stenosis, or prosthetic heart valve; or
(iii) AF with at least three criteria of intermediate risk of embolic
events: hypertension, diabetes, and left ventricular ejection fraction
,35% or age .75 years; (iv) intracavitary thrombi protruding into
the cardiac chambers; and (v) recent deep venous thrombosis (,3
months). Patients were randomized in two groups: the ﬁrst switched
from OAC to i.v. heparin (heparin group) and the other maintained
OAC with acenocumarol, a vitamin K antagonist (OAC group).
In the heparin group, OAC was discontinued 4 days before implant/
replacement; i.v. heparin was started at INR   2 and stopped 6 h
before the implant. After the procedure, OAC was reinstituted at
night and i.v. heparin was started 24 h after the implant with i.v.
bolus of 60 U/kg (maximum dosage of 4000 U) and an infusion rate
that maintained activated partial thromboplastin time between 55
and 70 s. Heparin perfusion was stopped at INR   2. In the OAC
group, INR was tested 15 days before implant to adjust acenocumarol
dosage to achieve an INR 2+0.3 at the day of the implant. After the
procedure, testing continued until an adequate INR was achieved.
All patients were evaluated at discharge, 15 and 45 days after the
procedure to assess pocket haematoma, thrombo-embolic events, or
other bleeding.
Deﬁnitions
Pocket haematoma was deﬁned as palpable mass that protruded
.2 cm anterior to pulse generator. Pocket haematoma was evacuated
if it caused tense swelling with poor capillary perfusion, progressive
enlargement, or severe pain to the patient.
5
Any thrombo-embolic event that took place between OAC dosage
modiﬁcation and 45 days after the procedure was recorded. Arterial
thrombo-embolic events were deﬁned as ischaemic stroke, TIAs, or per-
ipheral arterial thrombo-embolism. Venous thrombo-embolic events
were deﬁned as acute symptomatic pulmonary embolism or acute
symptomatic deep venous thrombosis. Prosthetic valve thrombosis
was only ruled out based on clinical symptoms. Echocardiograms
were not systematically obtained before and after the implant.
Surgical techniques
All procedures were performed in our centre by two experienced
electrophysiologists and one fellow in electrophysiology (L.M., A.B.,
and J.M.T.). More than 500 devices are implanted each year, and
each of the three physicians implants approximately one-third of
them. The number of years of experience in implanting devices
when the study started was as follows: L.M., 10 years; A.B., 6 years;
and J.M.T., 1 year.
New implant
Implants were done according to our institutional protocol. After
administration of prophylactic antibiotic and local anaesthesia, leads
were implanted through subclavian vein (one puncture per lead)
under ﬂuoroscopic guidance. Most ventricular leads had passive ﬁx-
ation except in the cases of severe tricuspid regurgitation or pulmon-
ary hypertension. Atrial leads on pacemakers had passive ﬁxation
except in patients with previous cardiac surgery. In patients treated
with cardiac resynchronization (CRT), all left ventricular leads were
inserted though the coronary sinus. As a general rule, in our depart-
ment, we follow the recommendation of current guidelines and
abandon the implant of the CRT after 4 h or 60 min of X-ray, if the
procedure is unsuccessful. Devices were placed in a subcutaneous
pocket localized in the pre-pectoral region. After the procedure, a
pressure dressing was applied to the wound for 6 h.
Replacement
After administration of the prophylactic antibiotic, an incision was
made, the generator was exteriorized and disconnected, and then
the leads were tested to conﬁrm the correct sensing, pacing
thresholds, and impedance parameters. The new generator was con-
nected and inserted into the existing pocket, the wound was closed
in layers, and a pressure dressing was applied for at least 6 h, or
until bleeding stopped.
Statistical methods
Based on our own experience, an incidence of 10% of pocket hae-
matoma and/or thrombo-embolic complications was expected in
the heparin group. A sample size of 50 patients per arm had
80% of power to detect an expected absolute difference of 24%
in the incidence of the primary endpoint in the OAC group,
using the two-sided Fisher’s exact test and with a signiﬁcance
level of 0.05. No loss to follow-up was expected.
Patients were randomly assigned to one study group by a
computer-generated randomization scheme in permuted blocks of
4 in equal proportions. The random sequence was performed and
kept by one statistician; patient treatment was entirely performed
bypersonnelunrelatedtothestudy;patientenrolment,implantpro-
cedure, and follow-up tasks were performed by the investigators.
Once the informed consent was obtained, one of the investigators
notiﬁed the inclusion of the patient and the statistician revealed
the group allocation only to the physician responsible for the pre-
implant treatment. Patient group was blinded to the investigators.
Data were analysed on an intention-to-treat basis.
Results were reported as mean+SD or using median (Q1–
Q3) as appropriate. Comparisons between continuous variables
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U-test. For categorical variables, the x
2 test or the exact method
was used. For the comparison of the number of leads implanted,
the Goodman and Kruskal Tau test was used. A two-sided
P-value of  0.05 was considered statistically signiﬁcant. Statistical
analyses were performed using the Statistical Package for the
Social Sciences (SPSS Inc.) 12.0.
Results
From September 2005 to October 2007, 101 consecutive patients
were included. No patient was lost during the follow-up or crossed
over between groups.
Baseline characteristics are shown in Table 1. No statistically sig-
niﬁcant baseline differences were observed between the groups in
this series. In both groups, most procedures were new implants:
41/51 (80.4%) in the heparin group vs. 38/50 (76%) in the OAC
group. There was no statistically signiﬁcant difference in the
number of leads implanted in each group (Table 2). Most of the
devices implanted/replaced in both groups were pacemakers: 36/
51 (70.6%) in the heparin group vs. 34/50 (68%) in the OAC
group. Mean INR at the time of implant was 1.1+0.2 vs. 2+
0.3 (P , 0.001) and the INR at 15 and 45 days of implant was
2.8+0.8 vs. 2.9+1( P ¼ 0.69) and 2.6+0.8 vs.2.7+0.5,
respectively (P ¼ 0.72), as shown in Figure 1.
Five implants in the OAC group had to be postponed because
the INR was too high; three of them were implanted the next
day and two were rescheduled until the INR was adequate. All
devices were successfully implanted. The mean duration of the
procedure was 120+40 min for three-lead devices, 65+40 min
for two-lead devices, and 44+30 min for one-lead devices.
Haematoma and embolic events
Pocket haematoma and/or thrombo-embolic events occurred in 4/
51 (7.8%) and in 4/50 (8.0%) patients of the heparin and OAC
groups up to 45 days after the procedure, respectively (OR:
1.022; 95% CI: 0.263–3.971; P ¼ 1.00). Pocket haematoma
occurred in four patients of each group at pre-discharge. Among
them, only one patient in each group required drainage, with no
need for blood transfusion. No new haematoma occurred after
discharge. In patients with haematoma, the mean drop in haemo-
globin was 26.8+3.7 g/L. No thrombo-embolic events occurred
in any patient of this series (Table 3).
Other complications
One patient from each group suffered a fatal endocarditis on the
prosthetic valve. In the heparin group patient, this was due to
Staphylococcus aureus and attributed to left-arm phlebitis. The
patient from the OAC group underwent a pacemaker implant
after a complete atrioventricular block following a mitral valve
replacement and subsequently developed a pocket infection and
prosthetic valve endocarditis. None of these two patients devel-
oped any haematoma at discharge.
One patient in the heparin group (1.9%) had a pneumothorax
that required evacuation and one patient in the OAC group (2%)
had a left ventricular lead displacement 1 day after implantation
that required a new intervention (Table 3).
In-hospital stay
Duration of the hospital stay had a median of 5 (Q1–Q3: 4–7
days) and 2 days (Q1–Q3: 1–4 days) in the heparin and AOC
groups, respectively (P , 0.001). The presence of pocket haema-
toma prior to discharge increased the mean in-hospital stay in
three patients.
...............................................................................................................................................................................
Table 1 Baseline characteristics of the patients included in the study
Heparin group (n 5 51) OAC group (n 5 50) P-value
Age (years) 66+11 68+10 0.28
Male sex 33 (65%) 30 (60%) 0.45
BMI (kg/m
2)2 5 +52 7 +5 0.62
New implant 41 (80%) 38 (76%) 0.36
ICD 15 (29.4%) 16 (32%) 0.88
Mechanical prosthetic valve 26 (51%) 28 (56%) 0.77
Mitral mechanical prosthetic valve 20 (39%) 19 (38%) 0.77
Mitro-aortic prosthetic valve 6 (12%) 9 (18%) 0.42
AF and prosthetic valve 17 (37%) 19 (38%) 0.73
Prosthetic valve þ ictus 10 (19%) 5 (10%) 0.15
AF and previous stroke 11 (21%) 14 (28%) 0.52
AF and  3 moderate risk factors 7 (14%) 5 (10%) 0.55
AF þ non-mechanical prosthetic valve 4 (8%) 2 (4%) 0.43
Protruding intracavitary thrombi 1 (2%) 1 (2%) 1.00
DVT or PTE 2 (4%) 0 (0%) 0.24
LVEF (%) 42.2+17 39.9+17 0.55
OAC, oral anticoagulants; LVEF, left ventricular ejection fraction; ICD, internal cardioverter deﬁbrillator; CRT, resynchronization device; AF, permanent, persistent or paroxysmal
atrial ﬁbrillation; HTA, hypertension; DVT, deep venous thrombosis; PTE, pulmonary thrombo-embolism; moderate risk factors: age  75, LVEF  35%, HTA, diabetes.
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To our knowledge, this is the ﬁrst randomized study to show that
OAC maintenance is as safe as bridging with i.v. heparin in the
implantation/replacement of a pacemaker or ICD in patients at
very high risk for thrombo-embolic events (e.g. .50% had
a mechanical prosthetic valve in the mitral position). Moreover,
the maintenance of OAC in these patients reduced the hospital
stay by a mean of 2.5+0.7 days. This is an important ﬁnding,
since shortening hospital stay will reduce admission costs impor-
tantly. Moreover, one may consider implanting pacemakers as an
outpatient procedure, as is currently done in patients without
OAC treatment.
A recent prospective observational study
10 has analysed the risk
of complete interruption of warfarin therapy in a large series of
patients who underwent minor interventions. A brief periproce-
dural interruption of OAC was associated with a low risk of
thrombo-embolism and haemorrhage. However, the population
included in this study was a heterogeneous group of patients
with widely differing thrombo-embolic risk among them. Our
study included only patients with high thrombo-embolic risk;
.50% of the population included in our study had a mechanical
prosthetic valve and 40% had a previous embolic event.
Current guidelines
4 recommend peri-operative bridging therapy
with heparin in this group of patients.
Safety of oral anticoagulation
maintenance
Other studies
7,8 have described the safety of implanting or replacing
a pacemaker or ICD while maintaining OAC, but these were obser-
vational and non-randomized trials. In our study, the incidence of
pocket haematomas was higher. Goldstein et al.
8 was a retrospec-
tive study and most of the procedures were replacements (62%); in
the Al-Kadra
7 study, 9/47 patients (19%) had a normal INR at the
time of the implant. Furthermore, the percentage of ICD and
CRT devices implanted in both studies was lower than in our
cohort of patients. The fact that the procedures in our series
were morecomplex mayaccountfor the difference inthe incidence
of pocket haematomas. Giudici et al.
11 postulated the safety of
implanting a pacemaker or ICD without stopping OAC and
reported on the biggest series of patients studied to date who
received a pacemaker or ICD without reversing OAC. The
authors of this study retrospectively analysed the data from a reg-
istry, comparing 470 patients with an INR . 1.5 at the moment
of the implant with 555 patients with an INR , 1.5 and found no
signiﬁcant difference in the incidence of pocket haematoma
between the two groups (2.5 vs. 1.6%, respectively). In this analysis,
the low incidence of pocket haematomas was similar between
those taking anticoagulants and those who were not. However,
these data were obtained in a retrospective analysis of a registry
that probably was not designed to evaluate bleeding and
thrombo-embolic events in high-risk patients. The patients were
evaluated by different physicians and there was no pre-established
deﬁnition of pocket haematoma. As a result, the study may under-
estimate the incidence of pocket haematomas. Furthermore, it was
not clear how many patients included in the anticoagulation group
had a high risk for thrombo-embolic events; therefore, it was
impossible to properly evaluate the incidence of embolic events
among these patients. Nevertheless, this study suggested that
implantation of these devices without stopping OAC is safe in
centres with experienced personnel. Milic et al.
12 demonstrated a
reduction in the percentage of pocket haematoma by applying
Figure 1 Comparison of mean INR levels registered at 15 days
pre-implant, day of implant, and 15 and 45 days post-implant,
between i.v. heparin and vitamin K antagonist groups. *P , 0.05.
................................................................................
Table 2 Number of leads implanted (patients with a






One lead 17/41 (41.5%) 16/38 (42.1%) 0.650
Two leads 12/41 (29.3%) 8/38 (21.1%)
Three leads 12/41 (29.3%) 14/38 (36.8%)
OAC, oral anticoagulants; one puncture per lead implanted.
................................................................................







Pocket haematoma 4/51 (7.8%) 4/50 (8%) 1.00
Drainage haematoma 1/51 (1.9%) 1/50 (2%) 1.00
Thrombo-embolic
events
0/51 (0%) 0/50 (0%) 1.00
Active endocarditis 1/51 (1.9%) 1/50 (2%) 1.00
Pneumothorax 1/51 (1.9%) 0/50 (0%) 0.49
Lead displacement 0/51 (0%) 1/50 (2%) 0.50
OAC, oral anticoagulants.
Preparation for pacemaker or ICD implants 1883a ﬁbrin sealant prior to wound closure, independent of maintaining
OAC or bridging to i.v. heparin. The number of patients included in
the study was small (20 patients in each group) and the percentage
of haematomas in the control group was high (25%). In our study,
the percentage of haematomas is 7.5% and only 2% of the
patients required evacuation. Although the use of pocket sealant
may be an option to minimize the number of pocket haematomas,
these products are expensive and may lead to other complications,
such as viral transmission, allergic reactions to bovine proteins,
accidental intravascular application of the product, or infections.
Other randomized studies with higher numbers of patients are
needed to demonstrate the safety and feasibility of these products.
Restarting i.v. heparin
In our study, 7.8% of the patients randomized to the i.v. heparin
arm developed pocket haematoma. There were no embolic
events. Although the study was not designed to determine the
best moment to restart i.v. heparin after the procedure, our
data suggest that restarting 24 h after the procedure decreases
the incidence of haematoma. In contrast with our ﬁndings,
Michaud et al.
5 found a pocket haematoma in 20% of the
patients, independent of restarting heparin 6 or 24 h after the
implantation.
Endocarditis
Two patients developed a fatal endocarditis, both with pre-
existing risk factors as described by Klug et al.
13 (pre-operatory
fever due to left-arm phlebitis secondary to intravenous line,
and previous mitral valve replacement during the same hospital
stay, with temporary pacing). The 2% infection is higher than
the one observed in a previous analysis published in our institution
(0.6%).
14 However, the present study has been performed in a
high-risk population with a high percentage of prosthetic mitral
valves.
Limitations
All OAC patients were treated with acenocumarol since this is the
main vitamin K antagonist used in Spain. The results of our study
could be extrapolated to other vitamin K antagonists, although
pre- and post-implant intervals might be different from other
drugs due to differences in half-life and metabolism.
Because of the small number of adverse events, and the small
sample size of our study, large and probably multicentre studies
with many more events are needed to get a deﬁnitive answer
for the management of these patients.
Conclusion
In centres with experienced operators, maintaining OAC at INR
levels of 2+0.3 during the implant or replacement of a pacemaker
or ICD in patients at high risk for thrombo-embolic events can be
as safe as bridging to i.v. heparin, with the beneﬁt of reducing both
the in-hospital stay and the cost of the procedure.
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